This morning I laid out my general approach to how I’d deal with PEDs and the Hall of Fame. The shorthand: I’m a discounter. I try my best to take the accomplishment of established PED users down a bit. In this way I’m making an extremely rough and dirty era adjustment. I know it’s not a bulletproof approach. Far from it. And whenever I offer it up I usually ask for people if they have better ideas to enlighten me, because there isn’t a great way to deal with it.
Brien over at IIATMS took me up on that this afternoon, offering a critique of my approach that, I must acknowledge, makes me feel somewhat uncomfortable with my approach:
To sum it all up, the “this player wouldn’t be Hall-worthy without ‘roids” premise seems superficially fair and nuanced, but getting below the surface it seems far too similar to the old “he just doesn’t feel like a Hall-of-Famer” chestnut to me, and I absolutely despise that standard. And that’s why, though I certainly understand the desire to try to find a nuanced way to view this question, ultimately I don’t think there’s any way to apply such a standard in anything approaching an objective or scientific faction.
I can’t really rebut that with any sort of force. But I’m still not comfortable with where Brien comes out, which is to totally ignore the potential impact of PED use and focus only on production.
There’s no perfect answer here. It’s a struggle for even a guy like me who is often called a steroids apologist.
With last Wednesday’s start against the Yankees, Mariners hurler Hisashi Iwakuma pushed his 2016 innings total up to 2016. That clears the 162-inning hurdle for his 2017 option to vest at $14 million. However, as Steve Adams of MLB Trade Rumors reports, the language in Iwakuma’s contract also stipulates that the right-hander finish the season without suffering a specific injury.
Iwakuma, 35, was in agreement with the Dodgers on a three-year contract back in December but failed the physical, which nullified the deal. He ended up signing with the Mariners on a one-year, $12 million deal with a full no-trade clause and club options for 2017 and ’18 that vest at specific inning thresholds (162 each or 324 for both seasons).
This season, Iwakuma has stayed healthy, making 26 starts to the tune of a 14-9 record, a 3.81 ERA and a 118/36 K/BB ratio in 163 innings.
Marlins outfielder Ichiro Suzuki deposited a single to left-center field in the fourth inning of Monday night’s game against the Mets, then added a double to center field in the eighth. Those mark hits No. 3,010 and 3,011 for Suzuki in his major league career, tying and then moving past Wade Boggs for sole possession of 27th on baseball’s all-time hits list.
Suzuki would come around to score on a double by Xavier Scruggs to break a scoreless tie in the eighth.
Here’s the video of Ichiro’s first hit.
By the end of the season, Suzuki will have presumably moved ahead of Rafael Palmeiro (26th; 3,020) and Lou Brock (25th; 3,023).
Suzuki was 2-for-4 after the double. With baseball’s fifth month nearly complete, the 42-year-old is currently batting .298/.371/.373.